{"id":"efonidipine","rwe":[{"pmid":"41794177","year":"2026","title":"Stabilization of supersaturation for enhanced oral absorption of a BCS II drug efonidipine hydrochloride: Eudragit® L100-55-based amorphous solid dispersions.","finding":"","journal":"Journal of pharmaceutical sciences","studyType":"Clinical Study"},{"pmid":"41625908","year":"2025","title":"Comparative Efficacy and Safety of Vasodilators Used to Prevent Internal Thoracic Artery Spasm in Coronary Artery Bypass Grafting: A Systematic Review.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41414781","year":"2025","title":"Innovative Analytical Methodologies for Quantification of Efonidipine HCl and Chlorthalidone: A Critical Review.","finding":"","journal":"Critical reviews in analytical chemistry","studyType":"Clinical Study"},{"pmid":"40821004","year":"2025","title":"The Application of Mesoporous Silica Nanoparticles in Enhancing the Efficacy of Anti-Atherosclerosis Therapies: A Review.","finding":"","journal":"International journal of nanomedicine","studyType":"Clinical Study"},{"pmid":"40624735","year":"2025","title":"A New Method for Antispastic Effect in Coronary Artery Bypass Grafts by Using a L- and T-Type Calcium Channel Blocker Efonidipine.","finding":"","journal":"Basic & clinical pharmacology & toxicology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent T-type calcium channel subunit alpha-1H","category":"target"},{"label":"CACNA1H","category":"gene"},{"label":"CACNA1C","category":"gene"},{"label":"CACNA1D","category":"gene"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"zeria","offLabel":[],"synonyms":["efonidipine","efonidipine hydrochloride","zeria","efonidipine HCl"],"timeline":[],"approvals":[],"brandName":"Zeria","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Voltage-dependent T-type calcium channel subunit alpha-1H","targets":[{"gene":"CACNA1H","source":"DrugCentral","target":"Voltage-dependent T-type calcium channel subunit alpha-1H","protein":"Voltage-dependent T-type calcium channel subunit alpha-1H"},{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"},{"gene":"CACNA1D","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1D"}],"modality":"Small Molecule","explanation":"Think of your blood vessels like a garden hose. When the T-type calcium channel is active, it's like someone is squeezing the hose, making it harder for blood to flow. By blocking this channel, Zeria helps to relax the blood vessels, making it easier for blood to flow and lowering blood pressure.","oneSentence":"Zeria works by blocking the T-type calcium channel, which helps to relax blood vessels and lower blood pressure.","technicalDetail":"Zeria exerts its effects by selectively inhibiting the voltage-dependent T-type calcium channel subunit alpha-1H, which is involved in the regulation of vascular smooth muscle tone and cardiac function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/992","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EFONIDIPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EFONIDIPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:56:58.489365","biosimilars":[],"competitors":[{"drugName":"pimozide","drugSlug":"pimozide","fdaApproval":"1984-07-31","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"efonidipine","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pimozide","brandName":"pimozide","genericName":"pimozide","approvalYear":"1984","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT02885558","phase":"NA","title":"Role of Calcium Channels in Vascular Function","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2017-11-01","conditions":["Endothelium, Vascular"],"enrollment":12,"completionDate":"2021-05-25"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010907","UNII":"40ZTP2T37Q","CHEBI":"CHEBI:135859","INN_ID":"6852","UMLSCUI":"C0286819","ChEMBL_ID":"CHEMBL2074922","KEGG_DRUG":"D07886","DRUGBANK_ID":"DB09235","PUBCHEM_CID":"119171","IUPHAR_LIGAND_ID":"12565","SECONDARY_CAS_RN":"111011-53-1","MESH_SUPPLEMENTAL_RECORD_UI":"C066425"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":169,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 5","pmid":"41794177","title":"Stabilization of supersaturation for enhanced oral absorption of a BCS II drug efonidipine hydrochloride: Eudragit® L100-55-based amorphous solid dispersions.","journal":"Journal of pharmaceutical sciences"},{"date":"2025 Dec","pmid":"41625908","title":"Comparative Efficacy and Safety of Vasodilators Used to Prevent Internal Thoracic Artery Spasm in Coronary Artery Bypass Grafting: A Systematic Review.","journal":"Cureus"},{"date":"2025 Dec 18","pmid":"41414781","title":"Innovative Analytical Methodologies for Quantification of Efonidipine HCl and Chlorthalidone: A Critical Review.","journal":"Critical reviews in analytical chemistry"},{"date":"2025","pmid":"40821004","title":"The Application of Mesoporous Silica Nanoparticles in Enhancing the Efficacy of Anti-Atherosclerosis Therapies: A Review.","journal":"International journal of nanomedicine"},{"date":"2025 Aug","pmid":"40624735","title":"A New Method for Antispastic Effect in Coronary Artery Bypass Grafts by Using a L- and T-Type Calcium Channel Blocker Efonidipine.","journal":"Basic & clinical pharmacology & toxicology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zeria (Efondipine) is a small molecule modality targeting the voltage-dependent T-type calcium channel subunit alpha-1H. It is used to treat hypertensive disorders. The commercial status of Zeria is currently unknown, and it is not clear if it is patented or available as a generic. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacological profile.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}